Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly
- 13 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.
- 03 May 2017 Planned End Date changed from 1 May 2017 to 1 Jul 2017.
- 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.